These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 27581765)
1. Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Aya F; Gaba L; Victoria I; Fernández-Martínez A; Tosca M; Prat A; Arance A Future Oncol; 2016 Dec; 12(23):2683-2688. PubMed ID: 27581765 [TBL] [Abstract][Full Text] [Related]
2. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830 [TBL] [Abstract][Full Text] [Related]
3. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347 [TBL] [Abstract][Full Text] [Related]
4. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333 [TBL] [Abstract][Full Text] [Related]
14. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424 [TBL] [Abstract][Full Text] [Related]
17. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Weber J; Gibney G; Kudchadkar R; Yu B; Cheng P; Martinez AJ; Kroeger J; Richards A; McCormick L; Moberg V; Cronin H; Zhao X; Schell M; Chen YA Cancer Immunol Res; 2016 Apr; 4(4):345-53. PubMed ID: 26873574 [TBL] [Abstract][Full Text] [Related]
18. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. Meerveld-Eggink A; Rozeman EA; Lalezari F; van Thienen JV; Haanen JBAG; Blank CU Ann Oncol; 2017 Apr; 28(4):862-867. PubMed ID: 28158487 [TBL] [Abstract][Full Text] [Related]
19. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies]. Robert C; Mateus C Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705 [TBL] [Abstract][Full Text] [Related]
20. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Ott PA; Hodi FS; Robert C Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]